-
Start Preamble
Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 14, 2005, and February 14, 2006, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II:
Drug Schedule Dihydrocodeine (9120) II Oxymorphone (9652) II The company plans to manufacture in bulk, for distribution to its customers, who are final dosage manufacturers.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than July 14, 2006.
Start SignatureDated: May 9, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E6-7338 Filed 5-12-06; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 05/15/2006
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- E6-7338
- Pages:
- 28052-28052 (1 pages)
- PDF File:
- e6-7338.pdf